Leniolisib

• Description:

  Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment.

• Product Name Alternative:

  CDZ173

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  PI3K

• Type:

  Reference compound

• Related Pathways:

  PI3K/Akt/mTOR

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Leniolisib.html

• Purity:

  99.38

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CCC (N1C[C@@H] (NC2=C (CN (C3=CC (C (F) (F) F) =C (OC) N=C3) CC4) C4=NC=N2) CC1) =O

• Molecular Formula:

  C21H25F3N6O2

• Molecular Weight:

  450.46

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406|[2]Hoegenauer K, et al. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. ACS Med Chem Lett. 2017 Aug 25;8 (9) :975-980.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ

• CAS Number:

  1354690-24-6